SAT-570 Should Severe Hypertriglyceridemia Also Be Considered as a Contraindication for Use of Glucagon like Peptide 1 (GLP-1) Agonists?
نویسندگان
چکیده
منابع مشابه
An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be...
متن کاملserum levels of glucagon-like peptide (glp)-1 and glp-2 in patients with hashimoto’s thyroiditis
background: the influence of hashimoto’s thyroiditis (ht) with subclinical hypothyroidism or euthyroid status on the alteration of glucagon-like peptide (glp)-1 and glp-2 levels remains uncertain. materials and methods: twenty-four untreated ht patients with subclinical hypothyroidism, 24 euthyroid ht patients, and 24 age- and gender-matched controls were enrolled in the study. the levels of gl...
متن کاملEffects of Fasting on Glucagon-like peptide-1 hormone (GLP-1), and Lipid Profile Indices in Obese and Thin Women
Introduction: Glucagon-like peptide-1 hormone (GLP-1) contributes to the regulation of insulin and glucose concentration. However, the effects of fasting on GLP-1 response in different people has not been determined yet. The aim of the present research was to investigate the effect of fasting on GLP-1 and the lipid profile of obese and thin women.Materials and methods: In this research, 25 obes...
متن کاملCardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a 2-4× increased incidence of death from coronary artery disease. Patients with diabetes are considered for cardiovascular disease secondary prev...
متن کاملTreatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
GLP-1 (glucagon-like peptide-1) is a peptide hormone secreted from endocrine cells in the intestinal mucosa in response to meals. The major effects of GLP-1 are to increase glucose-induced insulin secretion and reduce glucagon release, but GLP-1 also inhibits gastric emptying rate and reduces appetite and bodyweight in obese subjects. In vivo studies using animal models of type 2 diabetes and i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Endocrine Society
سال: 2020
ISSN: 2472-1972
DOI: 10.1210/jendso/bvaa046.242